OncoSec Announces Initiation of a Phase 2 Study at the Moffitt Cancer Center to Evaluate the Combination of TAVO plus OPDIVO® as Neoadjuvant Therapy for Melanoma Aug 27, 2020 8:30am EDT
OncoSec Medical Incorporated Announces Proposed Public Offering of Common Stock Aug 14, 2020 8:42pm EDT
OncoSec to Present at the BTIG Virtual Biotechnology Conference 2020 on Tuesday, August 11, 2020 Aug 10, 2020 8:30am EDT
OncoSec's Novel COVID-19 Vaccine Candidate Featured in 'Straight Talk' Program by NBC TV in Portland, Oregon Jul 13, 2020 9:00am EDT
OncoSec to be Featured in "Grand Rounds: a Webinar in Biotech and Specialty Pharma," Webinar Hosted by Alliance Global Partners Jul 09, 2020 9:00am EDT
OncoSec Presents Two Late-Breaking Abstracts on TAVO-PLUS at the American Association for Cancer Research (AACR) Virtual Annual Meeting II Jun 22, 2020 9:05am EDT
